NDAINHALATIONLIQUIDPriority Review
Approved
Dec 1979
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
5/8 — Partial
Priority Review
FORANE (isoflurane) by Baxter International is 12. First approved in 1979.
Drug data last refreshed 15h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FORANE (isoflurane) is a volatile general anesthetic administered via inhalation for induction and maintenance of anesthesia during surgery. It works by rapidly inducing anesthesia with mild pungency, readily obtunding pharyngeal and laryngeal reflexes, and maintaining stable heart rhythm while producing profound respiratory depression and muscle relaxation. Isoflurane enables rapid changes in anesthetic depth and is commonly combined with nitrous oxide to reduce required concentrations.
LOE Approaching
As an established inhalational anesthetic approaching loss of exclusivity, FORANE operates in a mature market with stable but limited team expansion opportunities focused on manufacturing efficiency and operational excellence.
Mechanism of Action
12.2 Pharmacodynamics Induction of and recovery from isoflurane anesthesia are rapid. Isoflurane has a mild pungency which limits the rate of induction, although excessive salivation or tracheobronchial secretions do not appear to be stimulated. Pharyngeal and laryngeal reflexes are readily…
Worked on FORANE at Baxter International? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.